CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

NewsGuard 100/100 Score

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

Data from these trials are expected to influence the practice of interventional cardiovascular medicine and have an immediate impact on guidelines and patient care. These featured trials will be highlighted during sessions throughout TCT.

TUESDAY, SEPTEMBER 21, 6:00 PM - 7:45 PM

  • SYNTAX Left Main: Three-Year Outcomes from a Prospective Randomized Trial of Paclitaxel-Eluting Stents Compared to Bypass Graft Surgery in Patients with Left Main Coronary Artery Disease
  • SYNTAX 3VD: Three-Year Outcomes from a Prospective Randomized Trial of Paclitaxel-Eluting Stents Compared to Bypass Graft Surgery in Patients with Triple Vessel Coronary Artery Disease
  • EXECUTIVE: A Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Multivessel Coronary Artery Disease
  • DECLARE-LONG II: A Prospective Randomized Trial of Triple vs. Dual Antiplatelet Therapy to Reduce Restenosis in Long Coronary Lesions Treated with Zotarolimus-Eluting Stents
  • DK-CRUSH-II: A Prospective Randomized Trial of Double Kissing Crush Stenting Compared to Provisional Stenting for Treatment of True Coronary Bifurcation Lesions
  • TRIAS High Risk: A Prospective Randomized Trial of Endothelial Progenitor Cell Capturing Stents Compared to Other Drug-Eluting Stents in Patients with Complex Coronary Artery Disease
  • ROMA: A Prospective Randomized Trial of Rosuvastatin Pretreatment Prior to Percutaneous Coronary Intervention
  • COMPARE-AMI: Two-Year Outcomes from a Prospective, Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with STEMI

WEDNESDAY, SEPTEMBER 22, 6:00 PM - 8:00 PM

  • LEADERS: Three-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
  • ESSENCE-DIABETES: A Prospective Randomized Trial of Everolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients with Diabetes Mellitus and Coronary Artery Disease
  • ZEST: Two-Year Outcomes from a Prospective, Randomized Trial of Sirolimus-Eluting Stents, Paclitaxel-Eluting Stents and Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
  • APPOSITION II: A Prospective Randomized Trial of Self-Expanding vs. Balloon Expandable Stents in Patients with Acute Myocardial Infarction
  • CLOVIS-2: A Prospective, Randomized, Nested Case-Control Crossover Study of a High vs. Low Clopidogrel Loading Dose in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele
  • PRO-GR: A Prospective, Randomized, Crossover Study of Maintenance High-Dose Clopidogrel vs. Prasugrel in Patients With and Without the CYP2C19*2 Loss-of-Function Allele
  • SOURCE TAVI Cohort 2: A Prospective Observational Study of More Than 2,300 Lower Risk and "Valve-in-Valve" Patients Undergoing Transcatheter Aortic Valve Implantation
  • PFO Closure: A Prospective Nonrandomized Propensity-Adjusted Study of PFO Closure Compared to Medical Therapy in Patients with Stroke Presumably Related to PFO

FRIDAY, SEPTEMBER 24, 6:00 PM - 8:00 PM

  • LANCELOT CAD: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Coronary Artery Disease
  • MYTHOS: A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy
  • ODS-CAS: A Prospective Randomized Trial of Iso-Osmolar Contrast Compared to Low-Osmolar Contrast to Prevent Contrast Nephropathy in Patients Undergoing Carotid Artery Stenting
  • STEM CELL MOBILIZATION: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Granulocyte Colony Stimulating Factor After Acute Myocardial Infarction in Patients with Low Left Ventricular Ejection Fraction
  • PREVENT-ICARUS: A Prospective, Randomized, Double-Blind Trial of Intracoronary Adenosine to Prevent Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Angioplasty
  • CRYSTAL AMI: A Prospective Randomized Trial of Intracoronary Site-Specific Abciximab Compared to Intravenous Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty
  • PEPCAD-CTO: A Prospective Nonrandomized Study of Paclitaxel-Eluting Balloons After Bare Metal Stent Placement in Successfully Recanalized Chronic Total Coronary Occlusions

Source: Cardiovascular Research Foundation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Natural compounds show promise in modulating heme breakdown, offering new therapeutic avenues